Table 2. TMEM165 expression in IDC vary by molecular subtypes.
Subtype | Hormonal Status | Percentage of Breast invasive carcinoma cases showing alterations in TMEM165 gene expressiona |
---|---|---|
Luminal A | ER+ and/or PR+, HER2, low Ki67 | 2% |
Luminal B | ER+ and/or PR+, HER2 (or HER2- with high Ki67) | 9% |
Triple negative/Basal like | ER-, PR-, HER2- | 15% |
Her 2 | ER-, PR-, HER2+ | 27% |
aDatabase used was The Cancer Genome Atlas (TCGA), Nature (2012).